Document:

Execution
Version

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

SUBLICENSE
AGREEMENT

 

THIS
SUBLICENSE Agreement (“Agreement”) is entered into this 17th day of August, 2017 (the “Effective
Date”) by and between ORTHOCYTE CORPORATION, a California corporation, having its principal place of business at 1010 Atlantic
Avenue, Suite 102, Alameda, CA 94501 (“OrthoCyte”), BIOTIME, INC., a California corporation, having its principal
place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”, and together with OrthoCyte,
“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at
1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).

 

WITNESSETH

 

WHEREAS,
pursuant to an exclusive license agreement with the University of Utah Research Foundation (“UURF”),
dated February 15, 2006, as amended (the “UURF License”), BioTime has obtained rights for the commercial
development, production, manufacture, use and sale of certain products that are Covered by the UURF Patents (as defined below);

 

WHEREAS,
AgeX is an Affiliate of BioTime; and

 

WHEREAS,
AgeX wishes to obtain from BioTime a license under certain rights for the commercial development, production, manufacture, use
and sale of certain products that are Covered by the UURF Patents, and BioTime is willing to grant such a license upon the terms
and conditions hereinafter set forth.

 

NOW
THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, the parties hereby agree
as follows:

 

ARTICLE
1. DEFINITIONS

 

1.1       “Actively
Commercializing” has the meaning set forth in Section.

 

1.2       “Affiliate”
means with respect to BioTime, AgeX or a Third Party, as the case may be, any Person or other entity that directly or indirectly
controls, is controlled by or is under common control with such other Person. For the purpose of this definition, “control”
means (a) the possession of the power to direct or cause the direction of the management and policies of such Person, whether
through ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of more than fifty
percent (50%) of the voting securities or other ownership interest of such Person.

 

    	 

    	 

    

 

1.3       “AgeX
Cellular Product” means any UURF Product that contains a Therapeutic Cell and is Covered by a Valid Claim of the
PureStem Patents, Brown Fat/Vascular Patents, or ESI Patents.

 

1.4       “AgeX
Field” means all uses for the treatment, palliation, diagnosis, or prevention of any human disease, disorder or
health condition excluding the BioTime Exclusive Field. For clarity, the AgeX Field shall not include [***].

 

1.5       “AgeX
iTR Product” means any UURF Product that contains a Cell Product and is Covered by a Valid Claim of the iTR Patents.

 

1.6       “AgeX
Product” means an AgeX iTR Product or AgeX Cellular Product.

 

1.7       “AgeX
Method” means a UURF Method necessary for the use or manufacture of an AgeX iTR Product or AgeX Cellular Product.

 

1.8       “BioTime
Exclusive Field” means products, medical devices, and services for the prevention, treatment, amelioration, diagnosis
or monitoring of (a) orthopedic indications, meaning [***]; (b) ophthalmological indications, meaning [***]; and (c) medical aesthetics
meaning [***].

 

1.9       “BioTime
Non-Exclusive Field” means products, medical devices, and services for the prevention, treatment, amelioration,
diagnosis or monitoring of disorders, degeneration, congenital conditions, or injuries of tendon, in each case, humans. For the
avoidance of doubt, the BioTime Non-Exclusive Field does not include the prevention, treatment, amelioration, diagnosis or monitoring
of disorders, degeneration, congenital conditions, or injuries of an orthopedic indication.

 

1.10       “Brown
Fat/Vascular Patents” means those patents listed on Exhibit A 

 

1.11       “Cell
Product” means any cell-based product that is intended for use as a therapeutic agent in humans.

 

1.12       “Change
of Control” means the occurrence of any of the following: (a) (a) any consolidation or merger of AgeX with or into
any Third Party, or any other corporate reorganization involving a Third Party, in which those persons or entities that are stockholders
of AgeX immediately prior to such consolidation, merger or reorganization own less than fifty percent (50%) of the surviving entity’s
voting power immediately after such consolidation, merger or reorganization; (b) a change in the legal or beneficial ownership
of fifty percent (50%) or more of the voting securities of AgeX (whether in a single transaction or series of related transactions)
where, immediately after giving effect to such change, the legal or beneficial owner of more than fifty percent (50%) of the voting
securities of AgeX is a Third Party; or (c) the sale, transfer, lease, license or other disposition of all or substantially all
of AgeX’s assets or business (or that portion thereof related to AgeX Products) in one or a series of related transactions
to a Third Party.

 

1.13       “Commercialization”
in respect of a particular product, any and all activities (whether before or after receipt of marketing approval in respect of
the product, medical device or service) directed to the marketing, detailing and promotion of the product or medical device after
marketing approval for such product has been obtained, and includes marketing, promoting, detailing, distributing, offering to
commercially sell and commercially selling the product, medical device or service, importing, exporting or transporting the product
or medical device for commercial sale, and regulatory affairs with respect to the foregoing. When used as a verb, “Commercializing”
means engaging in Commercialization and “Commercialize” and “Commercialized”
shall have corresponding meanings.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

1.14       “Commercially
Reasonable Efforts” means, with respect to the efforts to be expended by any party and with respect to any objective,
the reasonable, diligent, good faith efforts to accomplish such objective as such party would use in its ordinary course of business
to accomplish a similar objective under similar circumstances. With respect to any objective relating to the research, development,
or exploitation as used herein, “Commercially Reasonable Efforts” means that level, caliber and quality of efforts
and resources reasonably and normally used in the Research, Development and Exploitation by biopharmaceutical companies for a
product that is of similar market potential and at a similar stage in its Development or product life, taking into account, without
limitation, issues of safety, efficacy, product profile, competitiveness in the marketplace, including efforts used by similarly
positioned competitors for competing products, regulatory structure involved, optimal timing for market entry, proprietary position,
and other relevant scientific, technical, business, marketing, return on investment, financial resources, and other commercial
factors. Without limiting the generality of the foregoing, “Commercially Reasonable Efforts, as it applies to the financial
matters herein, means adherence to the budgeting and staffing targets and timelines (to the extent adherence to such activities
and timelines are controllable by the party responsible for performing such activities).

 

1.15       “Confidential
Information” means all information and know-how and any tangible embodiments thereof provided by or on behalf of
one party to the other party either in connection with the discussions and negotiations pertaining to this Agreement or in the
course of performing under this Agreement, which may include data, knowledge, practices, processes, ideas, research plans, formulation
or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel
matters relating to the disclosing party or to its present or future products, sales, suppliers, customers, employees, investors
or business; provided, that, information or know-how of a party will not be deemed Confidential Information of such party for
purposes of this Agreement if such information or know-how: (a) was already known to the receiving party, other than under an
obligation of confidentiality or non-use, at the time of disclosure to such receiving party, as can be shown by written records;
(b) was generally available or known to parties reasonably skilled in the field to which such information or know-how pertains,
or was otherwise part of the public domain, at the time of its disclosure to such receiving party; (c) became generally available
or known to parties reasonably skilled in the field to which such information or know-how pertains, or otherwise became part of
the public domain, after its disclosure to such receiving party through no fault of the receiving party; (d) was disclosed to
such receiving party, other than under an obligation of confidentiality or non-use, by a Third Party who had no obligation to
the disclosing party not to disclose such information or know-how to others, as can be shown by written records; or (e) was independently
discovered or developed by such receiving party, as can be shown by its written records, without the use or benefit of, or reliance
on, Confidential Information belonging to the disclosing party.

 

    	 

    	 

    

 

1.16       “Control”
means, with respect to any Patent(s), possession of the right, whether directly or indirectly, and whether by ownership, license
or otherwise, to grant a license, sublicense or other right to or under such Patent(s) as provided for herein or, in the case
of ESI Patents or PureStem Patents, the applicable license agreement with BioTime or a BioTime Affiliate granting AgeX a license
or sublicense thereto, without violating the terms of any agreement or other arrangement with any Third Party.

 

1.17       “Cover”
means (i) for purposes of the UURF Patents, that a product, when made, used, or sold, or that a method, procedure, process, when
practiced, would constitute, but for the license granted to Licensee pursuant to this Agreement, an infringement of any claim
or claims included within the UURF Patents and (ii) for purposes of any Brown Fat/Vascular Patent, ESI Patent, iTR Patent, or
PureStem Patent, that the use, manufacture, sale, offer for sale, development, commercialization or importation of the subject
matter in question by an unlicensed entity would infringe a Valid Claim of such Brown Fat/Vascular Patent, ESI Patent, iTR Patent,
or PureStem Patent, as applicable.

 

1.18       “Development”
means all activities related to stability testing, process development, formulation, manufacturing scale-up, qualification and
validation, quality assurance/quality control, clinical studies, including manufacturing in support thereof, statistical analysis
and report writing, the preparation pre-submission and submission of INDs, premarket approvals, 510(k)s, NDAs, BLAs, and other
regulatory applications, filings or submissions, regulatory affairs with respect to the foregoing, and all other activities necessary
or reasonably useful or otherwise requested or required by the FDA or a comparable foreign regulatory authority as a condition
or in support of obtaining or maintaining a regulatory marketing approval, or an approval for a clinical trial, anywhere in the
world. When used as a verb, “Develop” means to engage in Development.

 

1.19       
“Effective Date” has the meaning set forth in the opening paragraph of this Agreement.

 

1.20       “ESI
Patents” means those patents listed on Exhibit B.

 

1.21       “Exploit”
means, to Develop, Manufacture, Commercialize, make, have made, use, offer to sell, sell or import; and “Exploitation”
means Developing, Manufacturing, Commercializing, making, having made, using, offering to sell, selling or importing.

 

1.22       “FDA”
means the United States Food and Drug Administration, or any successor agency.

 

1.23      
“Insolvent” means being unable to meet one’s debt obligations to another Entity as such debt
obligations become due and not being able to provide reasonable financial assurances of becoming able to meet such
obligations.

 

1.24       “iTR
Patents” means those Patents listed on Exhibit C.

 

    	 

    	 

    

 

1.25       “Manufacture”
and “Manufacturing” means, in respect of a particular pharmaceutical, bio-pharmaceutical, diagnostic,
or prognostic product, and without limitation, all activities related to the production, manufacture, processing, formulation,
filling, finishing, packaging, labeling, shipping, handling, holding, storage and warehousing of such product or any intermediate
thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial
manufacture and analytic development, product characterization, stability testing, quality assurance and quality control.

 

1.26       “Net
Sales” means gross revenue, monies, cash equivalent and/or transfer for any consideration, including revenue neutral
remuneration received by AgeX, its Affiliates, or any Sublicensee (as defined below), for (a) any AgeX Product sold or leased,
and (b) services performed using any AgeX Product or AgeX Method, in all cases, net of the sum of the following items directly
attributable to the sale of such AgeX Product or AgeX Method and specifically identified on the invoice, and borne by the seller
: (1) cash, trade or quantity discounts actually allowed; (2) sales, use, tariff, customs duties or other excise taxes directly
imposed upon particular sales; (3) outbound transportation charges prepaid or allowed; and (4) allowances or credits to third
parties for rejections or returns. An AgeX Product and services performed using a AgeX Product or AgeX Method shall be considered
sold when billed out or invoiced or, if not invoiced, when delivered or performed. There shall be no deductions from Net Sales
for costs of commissions or collections.

 

1.27       “Patents”
means (a) all national, regional and international patents and patent applications, including provisional patent applications;
(b) all patent applications filed either from such patents, patent applications or provisional applications or from an application
claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals
and continued prosecution applications; (c) any and all patents that have issued or in the future issue from the foregoing patent
applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention; (d) any
and all extensions (including patent term extensions) or restorations by existing or future extension or restoration mechanisms,
including revalidations, reissues, refilings, renewals, reexaminations and extensions (including any supplementary protection
certificates and the like) of the foregoing patents or patent applications ((a), (b), and (c)); and (e) any similar rights, including
so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or
patent of additions to any of such foregoing patent applications and patents, including any equivalents of the foregoing in any
part of the world.

 

1.28       “Person”
means any individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity
or organization, including a government or political subdivision, department or agency of a government.

 

1.29       “PureStem
Patents” means those patents listed on Exhibit D 

 

1.30       “Qualified
AgeX Product” means an AgeX Product for which AgeX has, following the Effective Date, expended at least [***] in
the performance of Research directly concerning such AgeX Product.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

1.31       “Research”
means performance of scientific experiments to answer questions not answerable or easily answerable through the published scientific
literature, pre-clinical and other non-clinical testing, test method development, and toxicology, formulation, and process development
work.

 

1.32       “Research
Product” means a UURF Product that comprises [***] in the formats available as of the Effective Date.

 

1.33       “Territory”
means worldwide, where patent coverage applies.

 

1.34       “Therapeutic
Cell” means a human cell that has been differentiated beyond the pluripotent and progenitor stages and has been
developed to have direct therapeutic activity.

 

1.35       “Third
Party” means any Person other than AgeX, BioTime, or their respective Affiliates.

 

1.36       “UURF
Method” means any method, procedure, process or other subject matter, the manufacture, use or sale of which is Covered
by any claim or claims included within the UURF Patents.

 

1.37       “UURF
Patents” means and include all of the following intellectual property: the United States patents and/or patent applications
listed in Exhibit E; United States patents issued from the applications listed in Exhibit E and from divisionals and continuations
(other than continuations-in-part) of these applications and any reissues of such United States patents; claims of continuation-in-part
applications and patents directed to subject matter specifically described in the applications listed in Exhibit E; and claims
of all foreign applications and patents which are directed to subject matter specifically described in the United States patents
and/or patent applications listed in Exhibit E.

 

1.38       “UURF
Product” means any product, apparatus, kit or component part thereof, or any other subject matter, the manufacture,
use or sale of which is Covered by any claim or claims included within the UURF Patents.

 

1.39       “Valid
Claim” means, in respect of any country: (a) any claim of an issued and unexpired Patent in such country that (i)
has not been held permanently revoked, unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction,
which decision is unappealable or unappealed within the time allowed for appeal and (ii) has not been abandoned, disclaimed, denied
or admitted to be invalid or unenforceable or disclaimer; and (b) a claim of a pending patent application in such country that
was filed and is being prosecuted in good faith and has not been abandoned or finally disallowed without the possibility of appeal
or re-filing of the application; provided that such prosecution has not been ongoing for more than ten (10) years.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

ARTICLE
2. LICENSE GRANT AND RELATED OBLIGATIONS

 

2.1       License
Grant. Subject to the terms and conditions set forth herein and in the UURF License, BioTime hereby grants to AgeX a non-exclusive
royalty-bearing sublicense in the Territory under the UURF Patents to (i) perform Research with respect to AgeX Products in the
AgeX Field and (ii) use, sell, offer for sale, Develop, and Commercialize any Qualified AgeX Product in the AgeX Field. This grant
is subject to the payment by AgeX to BioTime of all consideration required under this Agreement, to any rights of, or obligations
to, the U.S. Government as set forth in Section, and is further subject to rights retained by UURF pursuant to the UURF License
to:

 

a)       publish
the general scientific findings from research conducted in whole or in part at the University of Utah related to UURF Patents;
and

 

b)       manufacture,
have manufactured, use, or transfer UURF Patents for research, teaching and other educationally-related purposes.

 

2.2       US
Government Rights and Obligations. The research leading to certain of the UURF Patents and technology Covered thereby was
funded in part by the U.S. Government, and the rights granted in Section above are subject to any rights the U.S. Government may
have pursuant to any grant funding agreement between the U.S. Government and UURF, the University of Utah, or BioTime and any
applicable law, rule, or regulation. Further, the parties agree that, notwithstanding any use of descriptive terms such as “exclusive”
in Section and elsewhere in this Agreement, the U.S. Government has certain rights with respect to such UURF Patents and the inventions
claimed thereby as set forth in 35 U.S.C. §202-212 and applicable regulations of Title 37 of the Code of Federal Regulations,
including a non-exclusive, non-transferable, irrevocable, paid-up license to practice or have practiced the inventions of such
UURF Patents for its own purposes, including but not limited to such a license in the general form attached hereto as Exhibit
F. If there is a conflict between any such grant funding agreement or applicable law, rule, or regulation and this Agreement,
the terms of such government agreement or applicable law, rule, or regulation shall prevail. AgeX agrees to comply (and to cause
its Affiliates and Sublicensees to comply) with all obligations resulting from such government funding and/or rights.

 

2.3       Qualified
Product Limitations. For any given AgeX Product, AgeX agrees that neither AgeX, its Affiliates, nor any Sublicensees may engage
in any Development or Commercialization of such AgeX Product until such time as such AgeX Product becomes a Qualified AgeX Product.

 

2.4       Sublicensing.
AgeX shall not be entitled to grant any sublicenses hereunder to any Affiliate or grant any Sublicenses hereunder to any Third
Party. 

 

2.5       Research
Supply. BioTime shall use Commercially Reasonable Efforts to supply AgeX with such reasonable amounts of Research Product
as may be reasonably requested in writing by AgeX for the sole purposes of performing Research permitted under this Agreement.
AgeX shall pay BioTime for any such Research Product supplied hereunder at a price equal to BioTime’s reasonable, documented,
fully-burdened costs to manufacture and supply such AgeX Products to AgeX, with payment therefor to be made to BioTime within
[***] calendar days of its delivery thereof to AgeX.1

 

1
NOTE: Parties to negotiate a customary and reasonable form of supply agreement providing for BioTime’s supply of AgeX
Products to AgeX for purposes of Development and Commercialization.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

ARTICLE
3. TERM OF AGREEMENT

 

This
Agreement shall be in full force and effect from the Effective Date until the end of the term of the last-to-expire of the UURF
Patents sublicensed under this Agreement unless otherwise terminated by operation of law or pursuant to the terms of this Agreement
or the UURF License.

 

ARTICLE
4. FEES & ROYALTIES

 

4.1       Running
Royalty. As consideration for the license under this Agreement, AgeX shall pay to BioTime an earned royalty of [***] of Net
Sales. Earned royalties shall accrue in each country for the duration of the UURF Patents in that country. If any patent or any
claim thereof included within the UURF Patents shall be found invalid by a court of competent jurisdiction and last resort, from
which decision no appeal may be taken, AgeX’s obligation to pay BioTime royalties based on such patent or claim or any claim
patentably indistinct therefrom shall cease as of the date of such decision. AgeX shall not, however, be relieved from paying
BioTime any royalties, fees, expenses, or other liabilities that accrued prior to the date of such decision or that are based
on any of the UURF Patents not the subject of such decision.

 

4.2       Minimum
Royalty. Commencing with the [***] and each [***], if the amount paid or due under Section with respect to Net Sales occurring
during such [***] period is less than [***], AgeX shall pay BioTime the difference between such amount paid or due under Section
for Net Sales occurring during such [***] period and [***]. Such payment shall be due within [***] of the end of such [***] period.

 

ARTICLE
5. COMMERCIAL DILIGENCE & MILESTONES

 

5.1       Commercial
Diligence. AgeX shall diligently proceed with the Research, Development, Manufacture, sale and use of AgeX Products in order
to make them readily available to the general public as soon as possible on commercially reasonable terms. AgeX shall continue
active, diligent marketing efforts for one or more AgeX Products throughout the term of this Agreement (“Actively
Commercializing”).

 

ARTICLE
6. CONFIDENTIALITY

 

6.1       Confidentiality
Obligations. The parties agree that, for the Term and [***] thereafter, each party will keep completely confidential and will
not publish, submit for publication or otherwise disclose, and will not use for any purpose except for the purposes contemplated
by this Agreement (or, in the case of BioTime, for purposes of complying with its obligations under the UURF License) any Confidential
Information of the other party. 

 

6.2       Authorized
Disclosure. Each party may disclose Confidential Information of the other party to the extent that such disclosure is: 

 

a)       made
in response to a valid order of a court of competent jurisdiction; provided, however, that such disclosing party will, to the
extent reasonably practicable, (i) first have given written notice to the other party and given such other party a reasonable
opportunity to take appropriate action and (ii) cooperate with such other party as necessary to obtain an appropriate protective
order or other protective remedy or treatment; provided, further, that in each case, the Confidential Information disclosed in
response to such court or governmental order will be limited to that information which is legally required to be disclosed in
response to such court or governmental order, as determined in good faith by counsel to the party that is obligated to disclose
Confidential Information pursuant to such order;

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

b)       otherwise
required to be disclosed by any applicable law, rule, or regulation (including, without limitation, the U.S. federal securities
laws and the rules and regulations promulgated thereunder) or the requirements of any stock exchange to which a party is subject;
provided, however, that the party that is so required to disclose will provide such other party with written notice of such disclosure
reasonably in advance thereof to the extent reasonably practicable and reasonable measures will be taken to assure confidential
treatment of such information, including such measures as may be reasonably requested by the disclosing party with respect to
such Confidential Information;

 

c)       made
by such party, in connection with the performance of this Agreement, to such party’s Affiliates, licensees or sublicensees,
directors, officers, employees, consultants, representatives or agents, or to other Third Parties, in each case on a need to know
basis and solely to use such information for business purposes relevant to and permitted by this Agreement, and provided that
(i) each individual and entity to whom such Confidential Information is disclosed is bound in writing to non-use and non-disclosure
obligations no less than substantially as restrictive as those set forth in this Agreement and (ii) the party making such disclosure
shall be liable for such Third Parties’ compliance with such obligations;

 

d)       made
by such party to existing or potential acquirers, existing or potential collaborators, licensees, licensors, sublicensees, investment
bankers, accountants, attorneys, existing or potential investors, merger candidates, partners, venture capital firms or other
financial institutions or investors for use of such information for business purposes relevant to this Agreement or for due diligence
in connection with the financing, licensing or acquisition of such party (or such party’s acquisition of, or merger with,
a Third Party), and provided that (i) each individual and entity to whom such Confidential Information is disclosed is bound in
writing to non-use and non-disclosure obligations (or in the case of attorneys or accountants, an equivalent professional duty
of confidentiality) at least as restrictive as those set forth in this Agreement and (ii) the party making such disclosure shall
be liable for such Third Parties’ compliance with such obligations; or

 

e)       in
the case of BioTime, made to UURF pursuant to the terms of the UURF License.

 

6.3       GRAMA.
AgeX acknowledges that UURF and the University of Utah are subject to the Utah Governmental Records Access and Management Act
(“GRAMA”), Section 63-2-101 et seq., Utah Code Ann. (1953), as amended, and that UURF has agreed
to keep confidential any information provided to UURF by BioTime that BioTime considers confidential, to the extent allowable
under GRAMA and as provided in Section 53B-16-301 et seq., Utah Code Ann. In order for AgeX’s Confidential Information
to be eligible for such protection under GRAMA, Confidential Information of AgeX disclosed to BioTime must be in written or other
tangible form, marked as proprietary, and accompanied by a written claim by AgeX stating the reasons that such information must
be kept confidential.

 

    	 

    	 

    

 

ARTICLE
7. QUARTERLY & ANNUAL REPORTS

 

7.1       Quarterly
Royalty Report. Within thirty (30) days after the first calendar quarter in which Net Sales first occur, and within thirty
(30) days after each calendar quarter thereafter, AgeX shall provide BioTime with a written report detailing all sales and uses,
if any, made of AgeX Products and AgeX Methods during the preceding calendar quarter, and detailing the amount of Net Sales made
during such quarter and calculating the royalties due pursuant to Sections and, hereof. Each report shall include at least the
following:

 

a)       number
of AgeX Products manufactured, leased and sold by and/or for AgeX, its Affiliates;

 

b)       accounting
for all AgeX Methods used or sold by and/or for AgeX, its Affiliates;

 

c)       accounting
for Net Sales, noting the deductions applicable as provided in Section;

 

d)       minimum
royalties due under Section , if applicable;

 

e)       running
royalties due under Section ;

 

f)       total
royalties due;

 

g)       the
amount spent on (i) Research for each AgeX Product and (ii) Development for each AgeX Product; and

 

h)       the
number of full-time equivalent employees working on AgeX Products and/or AgeX Methods.

 

Each
report shall be in substantially similar form as Exhibit G attached hereto. Each such report shall be signed by an officer of
AgeX (or the officer’s designee). With each such report submitted, AgeX shall pay to BioTime the royalties and fees due
and payable under this Agreement. If no royalties shall be due, AgeX shall so report. AgeX’s failure to submit a royalty
report in the form required above will constitute a breach of this Agreement. AgeX will continue to deliver such reports to BioTime
after the termination or expiration of this Agreement until such time as all AgeX Product(s) permitted to be sold after termination
have been sold or destroyed.

 

7.2       Progress
Report and Commercialization Plan. Commencing on the Effective Date, and on each January 1 and July 1 thereafter, until the
first occurrence of Net Sales and annually thereafter each January 1, AgeX shall submit to BioTime a written report covering AgeX’s
progress in (a) development and testing of all AgeX Products and AgeX Methods; (b) achieving the due diligence milestones specified
herein; and (c) preparing, filing, and obtaining of any approvals necessary for marketing the AgeX Products and AgeX Methods and
(d) plans for the upcoming year in commercializing the AgeX Product(s). Each report shall be in substantially similar form and
contain at least the information required by Exhibit H attached hereto and incorporated herein.

 

    	 

    	 

    

 

7.3       Reporting
First Foreign Sales. In addition to the regular reports required by Sections and , AgeX shall provide a written report to
BioTime of the date of first occurrence of Net Sales in each country within thirty (30) days of its occurrence.

 

ARTICLE
8. PAYMENTS, RECORDS AND AUDITS

 

8.1       Payments.
AgeX shall pay all royalties accruing to BioTime in U.S. Dollars, without deduction of exchange, collection, wiring fees, bank
fees, or any other charges, within [***] following the calendar quarter in which Net Sales occur. All payments to BioTime will
be made in United States dollars by wire transfer or check payable to “BioTime, Inc.” and sent to:

 

BioTime,
Inc.

1010
Atlantic Avenue

Suite
102

Alameda,
California 94501

Attention:
Accounts Payable

Email:
AP@biotimeinc.com

 

8.2       Late
Payments. In the event any payments or other fees are not received by BioTime when due
hereunder, AgeX shall pay to BioTime interest charges at the rate of [***] per annum
on the amount of such payments or fees that were not paid by the date due for the reporting period.

 

8.3       Foreign
Exchange. With respect to Net Sales invoiced in a currency other than U.S. dollars, such Net Sales will be converted
into the U.S. dollar equivalent using the average conversion rate existing in the United States (as reported in The Wall Street
Journal, New York edition) during the applicable calendar quarter. If The Wall Street Journal ceases to be published, then the
rate of exchange to be used shall be that reported in such other business publication of national circulation in the United States
on which the parties reasonably agree. 

 

8.4       Blocked
Currency. In each country where the local currency is blocked and cannot be removed from the country, payments under
this Agreement arising from activities in that country for which AgeX, or an Affiliate thereof, does not receive payment in U.S.
currency, freely useable outside of such country, shall, notwithstanding anything to the contrary, be paid to BioTime in U.S.
Dollars

 

8.5       Records.
AgeX shall keep, and cause its Affiliates to keep, complete, true and accurate records and books containing all particulars that
may be necessary for the purpose of showing the amounts payable to BioTime hereunder. Records and books shall be kept at AgeX’s
principle place of business or the principal place of business of the appropriate division of AgeX to which this Agreement relates.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

8.6       Audit.
Said books and the supporting data shall be open at all reasonable times for five (5) years following the end of the calendar
year to which they pertain, to inspection by BioTime, UURF, or their agents, upon reasonable prior notice to AgeX, for the purpose
of verifying AgeX’s royalty statement or compliance in other respects with this Agreement. Such access will be available
to BioTime and UURF upon not less than ten (10) days written notice to AgeX, not more than once each calendar year of the Term
for each of BioTime and UURF, during normal business hours, and once a year for each of BioTime and UURF for three years after
the expiration or termination of this Agreement. Should such inspection lead to the discovery of a greater than [***], discrepancy
in reporting to BioTime’s detriment, AgeX agrees to pay the full cost of such inspection. Whenever AgeX has its books and
records audited by an independent certified public accountant, AgeX will, within fifteen (15) days of the conclusion of such audit,
provide BioTime with a written statement, certified by said auditor, setting forth the calculation of royalties due to BioTime
over the time period audited as determined from the books and records of AgeX.

 

ARTICLE
9. PATENT PROSECUTION, MAINTENANCE, AND DEFENSE

 

9.1       Prosecution,
Maintenance, and Defense. BioTime will, as between the parties, (i) use Commercially Reasonable Efforts to cause UURF to prosecute
and maintain the UURF Patents pursuant to the UURF License and (ii) control all prosecution, filing, and defense of the UURF Patents,
provided that BioTime will use Commercially Reasonable Efforts, taking into account the terms of the UURF License, to provide
AgeX copies of documents prepared by or received from patent counsel related to the prosecution and/or maintenance of the UURF
Patents to AgeX for review and comment prior to filing to the extent practicable under the circumstances.

 

9.2       Patent
Expenses. AgeX will be billed and will pay [***] of all reasonable, documented costs and fees and other charges incurred by
BioTime with respect to the preparation, prosecution, maintenance, and defense of the UURF Patents within [***] of receipt of
invoice from the selected patent attorney or from BioTime. 

 

9.3       Patent
Challenge. In the event AgeX, or its Affiliate (s)challenges the validity, enforceability or scope of any of any UURF Patent(s)
or claims thereof by legal or administrative action or proceeding or otherwise, or causes or enables any Third Party to undertake
such a challenge (a “Patent Challenge”):

 

(a)       BioTime
shall be entitled to terminate this Agreement on written notice to AgeX;

 

(b)       AgeX
shall provide [***] prior written notice of such Patent Challenge and provide BioTime all materials, information, opinions, and
analyses to be used to support such challenge;

 

(c)       [***];
and

 

(d)       all
amounts due or payable under will be doubled with respect to any payments due or triggered during the pendency of any Patent Challenge.
If the outcome of such Patent Challenge is a determination against the party or parties making, causing, or enabling such Patent
Challenge (the “Challenging Party”), such payments shall remain at such doubled amount for the remainder of
the Term. If the outcome of such Patent Challenge is a determination in favor of the Challenging Party, AgeX will have no right
to recoup any amounts paid under this Agreement before or during the pendency of such Patent Challenge.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

ARTICLE
10. PATENT MARKING

 

AgeX
shall permanently and legibly mark all AgeX Products made, used, sold, or otherwise disposed of by AgeX, any Affiliate thereof,
or their containers, (i) in accordance with patent notice appropriate under Title 35, United States Code or any similar law in
any foreign jurisdiction and (ii) with any other notice of patent rights reasonably necessary, in any country where AgeX Products
are sold, to (a) enable UURF Patents (to the extent, in each case, relating to AgeX Products) to be enforced to their full extent
or (ii) ensure the availability of all potential legal or equitable remedies with respect to any infringement of any UURF Patents
(to the extent, in each case, relating to AgeX Products) by any Third Party.

 

ARTICLE
11. TERMINATION BY BIOTIME

 

11.1       AgeX
Violations. If AgeX should: (a) fail to deliver to BioTime any statement or report required hereunder when due; (b) fail to
make any payment at the time that the same should be due; (c) violate or fail to perform any covenant, condition, or undertaking
of this Agreement to be performed by it hereunder; (d) cease Actively Commercializing AgeX Product(s); or (e) file a bankruptcy
action, have a bankruptcy action against it, become Insolvent, enter into a composition with creditors, or have a receiver appointed
for it, then, in the case of (a), (b), (c), (d), or (e), BioTime may give written notice of such default to AgeX. If AgeX should
fail to cure such default within [***] of such notice, the rights, privileges, and license granted hereunder shall automatically
terminate.

 

11.2       Business
Failure. If AgeX shall cease to carry on its business with respect to the rights granted in this Agreement, this Agreement
shall terminate upon [***] written notice by BioTime.

 

11.3       Affiliate.
This Agreement is being granted under Section 2.3 of the UURF license. If AgeX ceases to be an Affiliate of BioTime, the date
on which AgeX ceases to be an Affiliate, the parties agree that this sublicense becomes a sublicense under Section 2.4 of the
UURF License. Accordingly, within [***] of the date that AgeX ceases to be an Affiliate, BioTime shall comply with Section 2.4(c)
of the UURF License.

 

11.4       Obligations
After Termination. No termination of this Agreement by BioTime shall relieve AgeX of its obligation to pay any monetary obligation
due or owing at the time of such termination and shall not impair any accrued right of BioTime. AgeX shall pay all attorneys’
fees and costs incurred by BioTime in enforcing any obligation of AgeX or accrued right of BioTime. , , , , , , , , , and Sections
, , , , and shall survive any termination of this Agreement,

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

ARTICLE
12. TERMINATION BY AGEX

 

12.1       Voluntary
Termination. AgeX may terminate this Agreement, in whole or as to any specified patent, at any time and from time to time
without cause, by giving written notice thereof to BioTime. Such termination shall be effective [***] after such notice and all
AgeX’s rights associated therewith shall cease as of that date

 

12.2       Obligations
After Termination. Any termination pursuant to Section shall not relieve AgeX of any obligation or liability accrued hereunder
prior to such termination, or rescind or give rise to any right to rescind any payments made or other consideration given to BioTime
hereunder prior to the time such termination becomes effective. Such termination shall not affect in any manner any rights of
BioTime arising under this Agreement prior to the date of such termination.

 

ARTICLE
13. DISPOSITION OF LICENSED PRODUCTS ON HAND

 

Upon
expiration or termination of this Agreement by either party, AgeX shall provide BioTime with a written inventory of all AgeX Products
in process of manufacture, in use or in stock. AgeX may dispose of any such AgeX Products within the [***] period following such
expiration or termination, provided, however, that AgeX shall pay royalties and render reports to BioTime thereon in the manner
specified herein.

 

ARTICLE
14. WARRANTY BY BIOTIME

 

14.1       Right
to License. BioTime warrants that it has the lawful right to grant the license set forth in this Agreement.

 

14.2       EXCEPT
AS EXPRESSLY PROVIDED IN SECTION, THE PARTIES ACKNOWLEDGE AND AGREE THAT NEITHER BIOTIME NOR UURF HAS MADE ANY REPRESENTATIONS
OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
IN NO EVENT SHALL UURF OR BIOTIME BE HELD RESPONSIBLE FOR ANY SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF AGEX’S,
OR ITS AFFILIATES’ PRACTICE OF ANY TECHNOLOGY COVERED BY ANY UURF PATENTS, EVEN IF BIOTIME OR UURF IS ADVISED IN ADVANCE
OF THE POSSIBILITY OF SUCH DAMAGES.

 

14.3       Limitations.
Nothing in this Agreement shall be construed as:

 

a)       a
warranty or representation by BioTime as to the validity or scope of any UURF Patents.

 

b)       a
warranty or representation by BioTime that anything made, used, sold or otherwise disposed of pursuant to any license granted
under this Agreement is or will be free from infringement of intellectual property rights of third parties.

 

c)       an
obligation by BioTime to bring or prosecute actions or suits against third parties for patent infringement, except as may expressly
be provided in hereof.

 

d)       conferring
by implication, estoppel or otherwise any license or rights under any patents of BioTime other than UURF Patents.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

ARTICLE
15. INFRINGEMENT

 

15.1       Knowledge
of Infringement. If either party learns of a claim of infringement of or by any UURF Patents with respect to the rights licensed
to AgeX under this Agreement, that party shall give written notice of such claim to the other party. BioTime shall, as between
the parties, have the sole and exclusive right to prosecute or terminate such infringement or otherwise enforce the UURF Patents
against any such infringer. AgeX may not bring suit for any infringement of the UURF Patents without AgeX’s prior written
consent. No settlement, consent judgment or other voluntary final disposition of any suit with respect to any infringement of
any UURF Patent may be entered into without the consent of BioTime.

 

15.2       Expense
and Proceeds from Legal Action. Any legal action concerning any infringement of the rights to UURF Patents granted hereunder
shall be at the expense of the party by whom suit is filed, hereinafter referred to as the “Litigating Party”.
Any damages or costs recovered by the Litigating Party in connection with any such legal action filed by it hereunder, and remaining
under the Litigating Party is reimbursed for its costs and expenses reasonably incurred in the lawsuit, and after any royalties
or other payments due to BioTime under are paid, shall be divided as follows: [***] of such damages or recoveries concerning the
infringement of rights granted to AgeX hereunder to AgeX, with BioTime retaining the remainder.

 

15.3       Cooperation
in Litigation Proceedings. AgeX and BioTime shall reasonably cooperate with each other in litigation proceedings instituted
hereunder, provided that such cooperation shall be at the expense of the Litigating Party, and such litigation shall be controlled
by the Litigating Party.

 

ARTICLE
16. INSURANCE

 

16.1       Insurance
Requirements. Beginning at the time any AgeX Product is being distributed, sold, or administered to humans (including, in
each case, for the purpose of obtaining any required regulatory approvals) by AgeX, or an Affiliate thereof, AgeX will, at its
sole cost and expense, procure and maintain commercial general liability insurance issued by an insurance carrier with an A.M.
Best rating of A or better in amounts not less than [***]. AgeX will have the Indemnitees named as additional insureds under such
insurance. All rights of subrogation will be waived against BioTime and its insurers. Such commercial general liability insurance
will provide (i) product liability coverage; (ii) broad form contractual liability coverage for AgeX’s indemnification under
this Agreement; and (iii) coverage for litigation costs. The specified minimum insurance amounts will not constitute a limitation
on AgeX’s obligation to indemnify the Indemnitees under this Agreement.

 

16.2       Evidence
of Insurance and Notice of Changes. AgeX will provide BioTime with written evidence of such insurance upon request of BioTime.
AgeX will provide BioTime with written notice of at least [***] prior to the cancellation, non-renewal, or material change in
such insurance.

 

16.3       Continuing
Insurance Obligations. AgeX will maintain such commercial general liability insurance beyond the expiration or termination
of this Agreement during (i) the period that any AgeX Product(s) developed pursuant to this Agreement is being commercially distributed
or sold by AgeX, any Affiliate thereof, or any agent of any of the foregoing; and (ii) for five (5) years after such period.

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

ARTICLE
17. WAIVER

 

No
waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed
a waiver as to any subsequent and/or similar breach or default.

 

ARTICLE
18. ASSIGNABILITY

 

Neither
this Agreement, nor any rights or obligations hereunder, are assignable or otherwise transferable, in whole or in part (including
by operation of law, merger, or other business combination), by AgeX without the prior written consent of BioTime. The failure
of AgeX to comply with the terms of this paragraph shall be grounds for termination of the Agreement by BioTime under . Any permitted
assignee of either Party shall, as a condition to such assignment, assume all obligations of its assignor arising under this Agreement
following such assignment. Any purported assignment by a party of this Agreement, or any of such party’s rights or obligations
hereunder, in violation of this shall be void. In the event of any assignment of this Agreement by a party requiring the other
party’s consent under this , the assigning Party shall pay the other Party [***] upon the consummation of such assignment.
In the event that written consent is provided by BioTime for the assignment of this Agreement in connection with (a) a Change
of Control of AgeX, (b) assignment of this Agreement by AgeX pursuant to this, or (c) any sale by AgeX of all or substantially
all of a portion of its assets or business constituting a particular AgeX Product line or business unit engaged in the Research,
Development or Commercialization of any AgeX Product, AgeX will pay BioTime a non-refundable fee of [***].

 

ARTICLE
19. INDEMNIFICATION; LIMITATION OF LIABILITY

 

19.1       UURF
Indemnity. AgeX shall indemnify, hold harmless and defend BioTime, the University of Utah, UURF, and their respective officers,
employees and agents, against any and all claims, suits, losses, damages, costs, liabilities, fees and expenses (including reasonable
fees of attorneys) resulting from or arising out of exercise of: (a) any license granted under this Agreement; or (b) any act,
error, or omission of AgeX, its agents, employees or Sublicensees, except where such claims, suits, losses, damages, costs, fees,
or expenses result solely from the negligent acts or omissions, or willful misconduct of the BioTime, its officers, employees
or agents. AgeX shall give BioTime timely notice of any claim or suit instituted of which AgeX has knowledge that in anyway, directly
or indirectly, affects or might affect BioTime, and BioTime shall have the right at its own expense to participate in the defense
of the same.

 

19.2       Indemnity
by AgeX. AgeX shall indemnify, defend and hold harmless BioTime, its Affiliates (other than AgeX and AgeX’s subsidiaries),
and their respective officers, directors, employees and agents (each a “BioTime Indemnified Party”), from and against
any and all Claims arising from or occurring as a result of the death or injury of any person caused or resulting (or allegedly
caused or resulting) from the use of any AgeX Product.:

 

(a)       any
default by AgeX of its obligations under this Agreement;

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

(b)       any
breach by AgeX of any of its representations and warranties set forth in this Agreement; and

 

(c)       any
negligent act or omission of AgeX in connection with the performance of its obligations under this Agreement;

 

Notwithstanding
the foregoing, AgeX shall not be required to indemnify BioTime, its Affiliates, and their respective officers, directors, employees
and agents for any Claim to the extent such Claim are attributable to any of the matters as to which BioTime has an obligation
to indemnify AgeX or for which the negligence, willful misconduct, or violation of any law by BioTime or any of BioTime’s
employees contributed to the death or injury that is the subject of the Claim.

 

19.3       Indemnity
by BioTime. BioTime shall indemnify, defend and hold harmless AgeX, its subsidiaries and their respective officers, directors,
employees and agents, from and against any and all costs, claims, damages and expenses (including reasonable attorneys’
fees and other expenses of legal proceedings) (collectively, “Claims”), in connection with any and all suits,
actions, investigations, claims or demands of Third Parties arising from or occurring as a result of any act or omission of BioTime.
Notwithstanding the foregoing, BioTime shall not be required to indemnify AgeX, its subsidiaries, and their respective officers,
directors, employees and agents for any Claims to the extent such Claims are attributable to any of the matters as to which AgeX
has an obligation to indemnify BioTime or for which AgeX’s negligence or willful misconduct contributed to the Claim.

 

19.4       Indemnification
Procedures.

 

a)       Notice
of Claim. In the event of any claim, action or proceeding for which a Person is entitled to indemnity hereunder, the Person seeking
indemnity (“Claimant”) shall promptly notify the relevant Party (“Indemnitor”) of such matter
in writing, but in no event shall the Indemnitor be liable for any Claim that result from any delay in providing such notice.

 

b)Control
of Defense.As its option, Indemnitor may then assume responsibility for and shall have full control of such matter by giving
notice to Claimant within thirty (30) days after the Indemnitor’s receipt of notice from Claimant. The assumption of the
defense of a Claim by the Indemnitor shall not be construed as an acknowledgment that Indemnitor is liable to indemnify Claimant
in respect of the Third Party claim, nor shall it constitute a waiver by Indemnitor of any defenses it may assert against Claimant’s
claim for indemnification. Upon assuming the defense of a Third Party claim, Indemnitor may appoint as lead counsel in the defense
of the Claim any legal counsel selected by Indemnitor. In the event Indemnitor assumes the defense of a Third Party claim, Claimant
shall immediately deliver to Indemnitor all original notices and documents (including court papers) received by Claimant in connection
with the Third Party claim. Should Indemnitor assume the defense of a Third Party claim, except as provided below, Indemnitor
shall not be liable to Claimant for any legal expenses subsequently incurred by such Claimant in connection with the analysis,
defense or settlement of the Third Party claim. In the event that it is ultimately determined that Indemnitor is not obligated
to indemnify, defend or hold harmless Claimant from and against the Third Party claim, Claimant shall reimburse Indemnitor for
any and all costs and expenses (including attorneys’ fees and costs of suit) and any Third Party claims incurred by Indemnitor
in its defense of the Third Party claim. Without limiting the foregoing, any Claimant shall be entitled to participate in, but
not control, the defense of such Claim and to employ counsel of its choice for such purpose; provided, however,
that such employment shall be at Claimant’s own expense unless (a) the employment thereof has been specifically authorized
by Indemnitor in writing, (b) Indemnitor has failed to assume the defense and employ counsel in accordance with this Section 19.4
(in which case Claimant shall control the defense) or (c) the interests of Claimant and Indemnitor with respect to such Claim
are sufficiently adverse to prohibit the representation by the same counsel of both Parties under applicable law, ethical rules
or equitable principles.

 

    	 

    	 

    

 

c)       Settlement.
With respect to any Claim relating solely to the payment of money damages in connection with a Claim and that shall not result
in Claimant’s becoming subject to injunctive or other relief or otherwise adversely affecting the business of Claimant in
any manner, and as to which Indemnitor shall have acknowledged in writing the obligation to indemnify Claimant hereunder, Indemnitor
shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Claim,
on such terms as Indemnitor, in its sole discretion, shall deem appropriate. With respect to all other Claim, where Indemnitor
has assumed the defense of the Claim in accordance with Section 9.4(b), Indemnitor shall have authority to consent to the entry
of any judgment, enter into any settlement or otherwise dispose of such Claim, provided it obtains the prior written consent
of Claimant (which consent shall not be unreasonably withheld or delayed). Indemnitor shall not be liable for any settlement or
other disposition of a Claim by Claimant that is reached without the written consent of Indemnitor. Regardless of whether Indemnitor
chooses to defend or prosecute any Third Party claim, no Claimant shall admit any liability with respect to or settle, compromise
or discharge, any Claim without the prior written consent of Indemnitor, such consent not to be unreasonably withheld or delayed.

 

d)       Cooperation.
Regardless of whether Indemnitor chooses to defend or prosecute any Third Party claim, Claimant shall cooperate in the defense
or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences,
discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall
include access during normal business hours afforded to Indemnitor to, and reasonable retention by Claimant of, records and information
that are reasonably relevant to such Third Party claim, and making employees and agents available on a mutually convenient basis
to provide additional information and explanation of any material provided hereunder, and Indemnitor shall reimburse Claimant
for all its reasonable out-of-pocket expenses in connection therewith.

 

e)       Expenses.
Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by Claimant in connection
with any claim shall be reimbursed on a calendar quarter basis by Indemnitor, without prejudice to Indemnitor’s right to
contest Claimant’s right to indemnification and subject to refund in the event Indemnitor is ultimately held not to be obligated
to indemnify Claimant.

 

f)       The
provisions of rather than this shall apply with respect to Claims arising from or pertaining to the infringement of any patent
rights.

 

    	 

    	 

    

 

19.5       Limitation
of Liability. UNDER NO CIRCUMSTANCES SHALL A PARTY HERETO BE LIABLE TO THE OTHER PARTY FOR CONSEQUENTIAL, INCIDENTAL, PUNITIVE
OR SPECIAL DAMAGES IN RESPECT OF PERFORMANCE OF THIS AGREEMENT; PROVIDED, HOWEVER, THAT ALL AMOUNTS THAT AN INDEMNIFIED PERSON
IS REQUIRED TO PAY TO ANY THIRD PARTY AS THE RESULT OF A MATTER FOR WHICH SUCH INDEMNIFIED PERSON IS ENTITLED TO BE INDEMNIFIED
UNDER THIS ARTICLE SHALL BE CONSIDERED TO BE DIRECT DAMAGES WHICH ARE INDEMNIFIABLE HEREUNDER.

 

ARTICLE
20. NOTICES

 

Any
payment, notice or other communication required or permitted to be given to either party hereto shall be in writing and shall
be deemed to have been properly given and effective: (a) on the date of delivery if delivered in person during recipient’s
normal business hours; or (b) on the date of attempted delivery if delivered by courier, express mail service or first-class mail,
registered or certified. Such notice shall be sent or delivered to the respective addresses given below, or to such other address
as either party shall designate by written notice given to the other party as follows:

 

In
the case of AgeX:

 

AgeX
Therapeutics, Inc.

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Attention: Michael D. West, Ph.D., CEO

Email:

 

In
the case of BioTime:

 

BioTime,
Inc.

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Attention:
Aditya Mohanty, CO-CEO

Email:

 

and

 

BioTime,
Inc.

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Attention:
General Counsel

Email:

 

    	 

    	 

    

 

ARTICLE
21. REGULATORY COMPLIANCE

 

21.1       Registration
of Agreement. When required by local/national law, AgeX shall register this Agreement, pay all costs and legal fees connected
therewith, and otherwise insure that the local/national laws affecting this Agreement are fully satisfied.

 

21.2       Compliance
With Law. AgeX shall comply, and shall ensure that its Affiliates and Sublicensees comply, with all applicable laws, rules
and regulations in the exercise of its rights and performance of its obligations hereunder, including but not limited to all laws,
rules, and regulations concerning the export and/or management of technology or information. AgeX understands that the Arms Export
Control Act (“AECA”), including its implementing International Traffic In Arms Regulations (“ITAR”)
and the Export Administration Act (“EAA”), including its Export Administration Regulations (“EAR”),
are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. AgeX further understands
that the U.S. export laws and regulations include (but are not limited to): (1) ITAR and EAR product/service/data-specific requirements;
(2) ITAR and EAR ultimate destination-specific requirements; (3) ITAR and EAR end user-specific requirements; (4) ITAR and EAR
end use-specific requirements; (5) Foreign Corrupt Practices Act; and (6) anti-boycott laws and regulations. AgeX will comply
with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations)
pertaining to the AgeX Product(s) (including any associated products, items, articles, computer software, media, services, technical
data, and other information). AgeX certifies that it will not, directly or indirectly, export (including any deemed export), nor
re-export (including any deemed re-export) the AgeX Product(s) (including any associated products, items, articles, computer software,
media, services, technical data, and other information) in violation of U.S. export laws and regulations or other applicable U.S.
laws and regulations. AgeX will include an appropriate provision in its agreements with its authorized Sublicensees to assure
that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and
regulations.

 

21.3       Location
of Manufacture. AgeX agrees that products used or sold in the United States embodying AgeX Products or produced through use
of the AgeX Method shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from
BioTime and the applicable government authority(ies).

 

ARTICLE
22. GOVERNING LAW

 

This
Agreement shall be governed by and construed in accordance with the laws of the State of California, without giving effect to
any conflict of laws principles or rules.

 

ARTICLE
23. RELATIONSHIP OF PARTIES

 

In
assuming and performing the obligations of this Agreement, AgeX and BioTime are each acting as independent parties and neither
shall be considered or represent itself as a joint venture, partner, agent or employee of the other.

 

    	 

    	 

    

 

ARTICLE
24. USE OF NAMES

 

24.1       By
AgeX. AgeX may not use the name of UURF, the University of Utah, or BioTime in connection with any name, brand or trademark
related to AgeX Products or AgeX Methods.

 

24.2       By
BioTime. BioTime, UURF, and the University of Utah may use AgeX’s name in connection with BioTime’s, UURF’s,
the University of Utah’s publicity related to their respective intellectual property and commercialization achievements.

 

ARTICLE
25. DISPUTE RESOLUTION

 

25.1       Good
Faith Discussions. In the event that any controversy or claim shall arise between the Parties under, out of, in connection with,
or relating to this Agreement or the breach thereof, the Party initiating such controversy or making such claim shall provide
to the other Party written notice containing a brief and concise statement of the initiating Party’s claims, together with
relevant facts supporting them. During a period of sixty (60) days, or such longer period as may be mutually agreed upon in writing
by the Parties, following the date of said notice, the Parties shall make good faith efforts to settle the dispute. Such efforts
may include, but shall not be limited to, full presentation of both Parties’ claims and responses, with or without the assistance
of counsel, before the chief executive officers (or their designees) of the Parties.

 

25.2       Arbitration.
In the event that the Parties have been unable to reach accord using the procedures set forth in Section and only if such is the
case, either Party may seek final resolution of the matter through binding arbitration, and only through binding arbitration.
The failure of a Party to comply with the provisions of Section with respect to any controversy or claim shall constitute an absolute
bar to the institution of any proceedings, by arbitration or otherwise, with respect to such controversy or claim. Any such arbitration
shall be held in San Francisco, California in the English language before a panel of three (3) arbitrators in accordance with
the then existing Rules of Arbitration of the American Arbitration Association (the “AAA”) and judgment upon the award
rendered by the arbitrators may be entered or enforced in any court having jurisdiction thereof. In any arbitration proceeding
hereunder, each Party shall select one arbitrator and the arbitrators selected by the Parties shall then select a third arbitrator,
who shall have at least fifteen (15) years’ experience in pharmaceutical patent licensing. The arbitrators shall permit
the Parties to have discovery to the extent permitted by the rules of the AAA. The decision of the arbitrators shall be final
and binding on the Parties and shall be accompanied by a written opinion of the arbitrators explaining the arbitrators’
rationale for their decision. The intent of the Parties is that except for the entering of an arbitration order in a court of
competent jurisdiction, disputes shall be resolved finally in arbitration as provided above, without appeal, and without recourse
to litigation in the courts.

 

25.3
Exceptions. Notwithstanding the foregoing provisions of Sections and , either Party may initiate an action before any court having
competent jurisdiction in order to obtain interim or conservatory relief, such as an order to preserve the status quo and to avoid
incurring irreparable harm pending the resolution of any dispute that is submitted to arbitration, to prevent or enjoin a breach
or threatened breach of confidentiality or to enforce provisions of this Agreement relating to ownership rights in intellectual
property without complying with the procedures set forth in Sections and .

 

    	 

    	 

    

 

ARTICLE
26. GENERAL PROVISIONS

 

26.1       The
headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect
the meaning or interpretation of this Agreement.

 

26.2       This
Agreement shall not be binding upon the parties until it has been signed herein below by or on behalf of each party, and as of
the Effective Date.

 

26.3       No
amendment or modification of this Agreement shall be valid or binding upon the parties unless made in writing and signed by both
parties.

 

26.4       This
Agreement embodies the entire understanding of the parties, and supersede all previous communications, representations or understandings,
either oral or written, between the parties relating to the subject matter hereof; provided, that the rights of AgeX with respect
to ESI Patents are subject to that certain License Agreement between AgeX and ES Cell International Pte, and the rights of AgeX
with respect to PureStem Patents are subject to that certain License Agreement between AgeX and BioTime.

 

26.5       The
provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid
or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not in any way affect the validity
or enforceability of the remaining provisions hereof.

 

26.6       This
Agreement may be signed in counterparts, each of which when taken together shall constitute one fully executed document. Each
individual executing this Agreement on behalf of a legal Person does hereby represent and warrant to each other person so signing
that he or she has been duly authorized to execute this Agreement on behalf of such Person.

 

26.7       In
the event of any litigation, arbitration, judicial reference or other legal proceeding involving the parties to this Agreement
to enforce any provision of this Agreement, to enforce any remedy available upon default under this Agreement, or seeking a declaration
of the rights of either party under this Agreement, the prevailing party shall be entitled to recover from the other such attorneys’
fees and costs as may be reasonably incurred, including the costs of reasonable investigation, preparation and professional or
expert consultation incurred by reason of such litigation, arbitration, judicial reference, or other legal proceeding.

 

[Signature
Page to Follow]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, BioTime and AgeX have executed this Agreement by their respective officers hereunto duly authorized, on the day
and year hereinafter written.

 

	AGEX
    THERAPEUTICS, INC.	 	BIOTIME,
    INC.
	 	 	 	 	 
	By	/s/
    Michael D. West	 	By	/s/
    Aditya P. Mohanty
	 	Michael
    D. West	 	 	Aditya
    P. Mohanty
	Title	Chief
    Executive Officer	 	Title	Co-Chief
    Executive Officer
	 	 	 	 	 
	Acknowledged
    and Agreed by:	 	 	 
	 	 	 	 	 
	ORTHOCYTE
    CORPORATION	 	 	 
	 	 	 	 	 
	By	/s/
    Michael D. West	 	 	 
	 	Michael
    D. West	 	 	 
	Title	Chief
    Executive Officer	 	 	 

 

[Signature
Page to the UURF Sublicense]

 

    	 

    	 

    

 

Execution
Version

 

EXHIBIT
A

 

Brown
Fat/Vascular Patents

 

	Matter No.	 	Title	 	Status	 	Application No.	 	Patent No.	 	Country
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

EXHIBIT
B

 

ESI
Patents

 

	Matter No.	 	Title	 	Status	 	Application No.	 	Patent No.	 	Country
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

EXHIBIT
C

 

iTR
Patents

 

	Matter No.	 	Title	 	Status	 	Application No.	 	Patent No.	 	Country
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

EXHIBIT
D

 

PureStem
Patents

 

	Matter No.	 	Title	 	Status	 	Application No.	 	Patent No.	 	Country	 	Owner
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

EXHIBIT
E

 

UURF
Patents

 

	Matter No.	 	Title	 	Status	 	Application No.	 	Patent No.	 	Assignee	 	Country
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED 

 

    	 

    	 

    

 

EXHIBIT
F

 

LICENSE
TO THE UNITED STATES GOVERNMENT

 

This
instrument confers to the United States Government, as represented by the __________, a non-exclusive, non-transferable, irrevocable,
paid-up license to practice or have practiced on its behalf throughout the world the following subject invention. This license
will extend to all divisions or continuations of the patent application and all patents or reissues, which may be granted thereon:

 

	 	Invention
    Title:	 
	 	 	 
	 	Inventor(s):	 
	 	 	 
	 	Patent
    Application Serial No.:	 
	 	 	 
	 	Filing
    Date:	 
	 	 	 
	 	Country,
    if other than United States:	 

 

This
subject invention was conceived and/or first actually reduced to practice in performance of a government-funded project, Grant
No.: __________.

 

Principal
rights to this subject invention have been left with the Licensor: University of Utah Research Foundation, subject to the provisions
of 37 CFR 401 and 45 CFR 8.

 

	Signed:	 	 	Date:	 
	Name:	 	 	Title:	President

 

    	 

    	 

    

 

Execution
Version

 

EXHIBIT
G

 

Quarterly
Report

For

_____
(title) _____, U-_____

 

	Date:	 	 
	 	 	 
	Period
    Covered:	 	 

 

	Royalties	 
	 	 
	A.	Number
    of units sold:	 
	 	 	 
	B.	Price
    per unit:	 
	 	 	 
	C.	Gross
    sales amount (AxB)	 
	 	 	 
	D.	Deductions:	 
	 	Discounts
    allowed (case, trade, quantity)	 
	 	Taxes
    impose on sales (sales, use, etc.)	 
	 	Transportation
    charges (outbound or prepaid)	 
	 	Allowances
    (rejections and returns)	 
	 	 	 
	 	Total
    Deductions	 
	 	 
	E.	Net
    Sales (C-D)	 
	 	 	 
	F.	Total
    royalty due (___% of E)	 
	 	 	 
	G.	Total
    royalty payment made	 

 

    	 

    	 

    

 

Execution
Version

 

EXHIBIT
H

 

Due
Diligence

For

_____
(title) _____, U-_____

 

	Date:	 	 
	 	 	 
	Period
    Covered:	 	 

 

Progress
Regarding Specific Due Diligence Milestones:

	 
	 
	 
	 
	 
	 
	 
	 
	 

 

	Projected
    Date of First Sale: 	 	 

 

Please
provide the commercial name of any FDA-approved products, utilizing this invention, that have first reached the market during
the designated reporting period. This information is necessary for federal funding reporting requirements.

 

	Product
    Name(s):	 
	 	 
	 	 
	 	 
	 	Yes	 	No	In
    the designated reporting period, did your company or any Sublicensee of the above referenced technology have 500 or more employees?
    This information is required to determine and report large or small entity status in the United States.
	 	 	 	 
	 	Yes	 	

                                                          

                                                         No
	

                                                                                 

                                                                                In the designated reporting period, did your company or any Sublicensee of the above referenced technology have more than 50 employees? This information is required to determine and report large or small entity status in Canada.FIRST
AMENDMENT TO SUBLICENSE AGREEMENT

 

THIS
FIRST AMENDMENT TO SUBLICENSE AGREEMENT (“First Amendment”) is entered into on November 8, 2017 (the “Effective
Date”) by and between ORTHOCYTE CORPORATION, a California corporation, having its principal place of business at 1010 Atlantic
Avenue, Suite 102, Alameda, CA 94501 (“OrthoCyte”), BIOTIME, INC., a California corporation, having its principal
place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“BioTime”, and together with OrthoCyte,
“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having its principal place of business at
1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).

 

WITNESSETH

 

WHEREAS,
the parties previously entered into a Sublicense Agreement (“Agreement”) on 17 August 2017 and now wish to clarify
the rights granted thereunder;

 

WHEREAS,
AgeX is an Affiliate of BioTime; and

 

NOW
THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, the parties hereby agree
as follows:

 

1. Section
1.3 of the Agreement shall be deleted and replaced in its entirety by:

 

“AgeX
Cellular Product” means any UURF Product that also contains a Therapeutic Cell.

 

2. Capitalized
terms used herein have the same meaning given to them in the Agreement.

 

3. Other
than expressly amended herein, the Agreement remains in full force and effect.

 

4. This
First Amendment may be executed in any number of counterparts.

 

[SIGNATURE
PAGE TO FOLLOW]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, BioTime and AgeX have executed this Agreement by their respective officers hereunto duly authorized, on the day
and year hereinafter written.

 

	AGEX
    THERAPEUTICS, INC.	 	BIOTIME,
    INC.
	 	 	 	 	 
	By	/s/
    Michael D. West 	 	By	/s/
    Aditya P. Mohanty
	 	Michael
    D. West	 	 	Aditya
    P. Mohanty
	Title	Chief
    Executive Officer	 	Title	Co-Chief
    Executive Officer

 

Acknowledged
and Agreed by:

 

	ORTHOCYTE
    CORPORATION	 
	 	 	 
	By	/s/
    Michael D. West 	 
	 	Michael
    D. West	 
	Title	Chief
    Executive Officer	 

 

[SIGNATURE
PAGE TO THE FIRST AMENDMENT TO THE UURF SUBLICENSE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]